Clinical trials: Oral Phase
HIV Infections
A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience
To assess the efficacy of enfuvirtide (Fuzeon) added to HAART compared to treatment with HAART alone in achieving and maintaining viral load suppression.
- Trial name
- INTENSE (NCT00487188)
- Testing
- Enfuvirtide, Highly active antiretroviral treatment (HAART)
- Where
- 39 sites in United States, Canada and 8 more
- Volunteers
- 47 people
- Sponsor
- Hoffmann-La Roche
Healthy Volunteers
Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and to Assess Effect of Food on the Pharmacokinetics (PK) of the Oral Suspension
The purpose of this study is to assess how much of apremilast is found in the blood unchanged when administered as an oral suspension compared to when it is administered as a tablet formulation.
- Trial name
- NCT02641353
- Testing
- Apremilast Tablet, Apremilast Oral Suspension
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Amgen
Patients With Newly Diagnosed Glioblastoma
A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
The study objectives are to assess the potential for PLX3397 to improve the efficacy of standard of care radiation therapy (RT) + temozolomide in patients with newly diagnosed glioblastoma (GBM).
- Trial name
- NCT01790503
- Testing
- PLX3397, Radiation Therapy, Temozolomide
- Where
- 9 sites in United States
- Volunteers
- 65 people
- Sponsor
- Daiichi Sankyo
Healthy Participants
A Study of PF-07258669 In Healthy Adult Participants
Part A of this study is to evaluate safety, tolerability, and pharmacokinetics (PK) of PF-07258669 after administration of multiple ascending oral doses to healthy adult participants.
- Trial name
- NCT05113940
- Testing
- PF-07258669, Midazolam
- Where
- Belgium
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Pfizer
Myelodysplastic Syndromes
Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes
Evaluate the safety and efficacy of oral azacitidne (CC-486) twice daily (BID) in subjects with myelodysplastic syndromes who failed to achieve an objective response post injectable hypomethylating agent (iHMA) treatment Reason…
- Trial name
- NCT02281084
- Testing
- Oral Azacitidine, Durvalumab
- Where
- 89 sites in United States, Australia and 8 more
- Volunteers
- 65 people
- Sponsor
- Celgene
Fungal Infection
Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension in Subjects at High Risk for Invasive Fungal Infections (P05520)
The purpose of this study is to collect pharmacokinetic (PK) information related to how well intravenous Posaconazole (POS IV), is distributed in the body and to determine the safety and tolerability of this new formulation.
- Trial name
- NCT01075984
- Testing
- Posaconazole, Dextrose 5% in water
- Volunteers
- 279 people
- Sponsor
- Merck Sharp & Dohme LLC
Malignant Melanoma
A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma
This open-label, non-randomized study will assess the mass balance, metabolism, routes and rates of elimination as well as efficacy and safety of RO5185426 (RG7204; PLEXXIKON; PLX4032) in previously treated or untreated patients…
- Trial name
- NCT01164891
- Testing
- RO5185426
- Where
- Switzerland
- Volunteers
- 7 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma, Hepatocellular Cancer
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
Background: A most common liver cancer in adults is hepatocellular carcinoma. Other kinds of liver cancer happen when colorectal or pancreatic cancer spreads to the liver.
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT03785210
- Testing
- nivolumab, tadalafil, oral vancomycin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Hypogonadism
Oral Testosterone for the Treatment of Hypogonadism
Low testosterone is a condition that occurs when the body is unable to produce sufficient quantities of testosterone. The medical name for low testosterone is hypogonadism. Hypogonadism can be caused by many factors.
- Trial name
- NCT01717768
- Testing
- TSX-002
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- TesoRx Pharma, LLC
Carcinoma, Non-Small-Cell Lung
BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)
The objectives of this trial are to estimate the following in Japanese patients with advanced NSCLC of stage IIIB/IV or with recurrence after failure of first-line chemotherapy.
- Trial name
- NCT00979576
- Testing
- BIBF 1120 M + Pemetrexed, BIBF 1120 H + Pemetrexed, BIBF 1120 RD + Pemetrexed
- Where
- 3 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
Sickle Cell Disease
Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of Voxelotor Administered Orally to Patients With Sickle Cell Disease
- Trial name
- GBT_HOPE (NCT03036813)
- Testing
- voxelotor
- Where
- 62 sites in United States, Canada and 10 more
- Volunteers
- 449 people
- Sponsor
- Pfizer
Healthy
A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants
The main purpose of this study is to evaluate the effect of pirtobrutinib (LOXO-305) on single oral dose of repaglinide (CYP2C8 substrate) when administered as multiple doses by conducting the blood tests to measure how much…
- Trial name
- NCT06165146
- Testing
- Repaglinide, Pirtobrutinib
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults
The purpose of this study is to evaluate the pharmacodynamics (the drug's effect on the body), the pharmacokinetics (the body's handling of the drug), and the safety and tolerability of vortioxetine, once daily (QD) in healthy…
- Trial name
- NCT01299805
- Testing
- Vortioxetine
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Takeda
Islet Cell Tumor
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
This study will estimate the treatment effect of everolimus in combination with pasireotide LAR relative to everolimus alone on progression-free survival (PFS) in patients with advanced progressive PNET.
- Trial name
- COOPERATE-2 (NCT01374451)
- Testing
- Everolimus, Pasireotide LAR
- Where
- 47 sites in United States, Argentina and 17 more
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Classical Hodgkin's Lymphoma
Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma
This study evaluated the efficacy of oral panobinostat in participants with refractory/relapsed classical Hodgkins lymphoma (HL) who have received prior treatment with high dose chemotherapy and autologous stem cell transplant.
- Trial name
- NCT00742027
- Testing
- Panobinostat
- Where
- 46 sites in United States, Australia and 11 more
- Volunteers
- 129 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Graft-versus-Host-Disease, Oral Mucosal Disease Due to Graft-versus-host Disease
An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease
This research study is evaluating the effectiveness of topical sirolimus combined with topical steroid therapy, as a possible treatment for oral cGVHD.
- Trial name
- NCT02123966
- Testing
- Sirolimus
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Dana-Farber Cancer Institute
Squamous Cell Carcinoma of the Head and Neck
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
This is a randomized, double-blind, multicenter, global Phase 3 study to assess the efficacy and safety of monalizumab and cetuximab, compared to placebo and cetuximab, in Participants with recurrent or metastatic head and neck…
- Trial name
- INTERLINK-1 (NCT04590963)
- Testing
- Monalizumab, Cetuximab
- Where
- 127 sites in United States, Argentina and 21 more
- Volunteers
- 370 people
- Sponsor
- AstraZeneca
Japanese Healthy Adult Male
A Bioequivalence (BE) Study of TAK-438 Orally Disintegrating (OD) Tablet
The purpose of this study is to evaluate the BE of single oral dose of TAK-438 OD 20 milligram (mg) tablet without water and TAK-438 20 mg tablet with water (Study 1), and TAK-438 OD 20 mg tablet with water and TAK-438 20 mg…
- Trial name
- NCT03808493
- Testing
- TAK-438 OD, TAK-438
- Where
- Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Takeda
Lung Cancer, Non-Small Cell
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
The current prognosis for patients with metastatic brain cancer from NSCLC is very poor. The current standard treatment for this disease is radiation therapy to the brain.
- Trial name
- NCT00390806
- Testing
- HYCAMTIN, oral capsules, Radiation
- Where
- 88 sites in United States, Canada and 4 more
- Volunteers
- 472 people
- Sponsor
- GlaxoSmithKline
Head and Neck Neoplasms
LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
This randomized, open-label, phase III study will be performed in patients with recurrent and/or metastatic head and neck cancer which has progressed after platinum-based therapy.
- Trial name
- NCT01856478
- Testing
- Methotrexate, Afatinib
- Where
- 53 sites in China, Egypt and 6 more
- Volunteers
- 340 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.